Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial

By afschroeder • August 25, 2026

Le X, Passaro A, Zhao Y, Huang Y, Laskin J, Rodriguez-Abreu D, Calles A, Bazhenova L, Lo Russo G, Leighl NB, Cappuzzo F, Girard N, Popat S, Fang W, Luo Y, Li W, He Z, Zhao H, Li M, Song Q, Zhao H, El Darsa H, Monnet I, Cobo Dols M, García Campelo R, Jotte R, Berz D, Spira A, Pérol M, Nagasaka M, West H, Styles L, Li J, Clow F, Goldman J, Zhang L. Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2026 Sep;27(9):1094-1109. doi: 10.1016/S1470-2045(26)00282-2. PMID: 42636833.

Tags: Hematology/Oncology, Publications

Rethinking the possibilities of adult ring sideroblastic anaemia

Carlson SG, Koo M, Dommaraju S, Song AH, Chai-Ho W. Rethinking the possibilities of adult ring sideroblastic anaemia. Lancet Haematol. 2026 Oct 6:S2352-3026(26)00133-X. doi: 10.1016/S2352-3026(26)00133-X.[...]

Topoisomerase-Based CDH17 Antibody Drug Conjugates Overcome P-gp Resistance but Undergo Target Mediated Clearance in Colorectal Cancer

O'Brien NA, Zhang J, Gong KW, McDermott MSJ, Hoffstrom B, Lu M, Liang M, Jia WP, Luo T, Madrid AM, Ayala R, Presta L, Larson[...]

Mosunetuzumab and Polatuzumab Vedotin as First-line Treatment for Large B Cell Lymphoma in Older Unfit or Frail Patients

Olszewski AJ, Eradat HA, Avigdor A, Horowitz NA, McKinney MS, Lee ST, Bergua Burgues JM, Rodriguez Izquierdo A, Bastos-Oreiro M, Ganzel C, Kim TM, Jeon[...]